Article Text

PDF
Gene therapy in cystic fibrosis
  1. David K Armstrong1,2,
  2. Steve Cunningham1,2,
  3. Jane C Davies1,3,4,
  4. Eric W FW Alton1,3,5
  1. 1UK CF Gene Therapy Consortium
  2. 2Department of Respiratory and Sleep Medicine, Royal Hospital for Sick Children, Edinburgh, UK
  3. 3Department of Gene Therapy, Imperial College London, London, UK
  4. 4Department of Paediatric Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UK
  5. 5Department of Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UK
  1. Correspondence to Dr David Armstrong, Department of Respiratory and Sleep Medicine, Royal Hospital for Sick Children, 9 Sciennes Road, Edinburgh, EH9 1LF, UK; david.armstrong{at}ed.ac.uk

Abstract

The principal cause of morbidity and mortality in cystic fibrosis (CF) is pulmonary disease, so the focus of new treatments in this condition is primarily targeted at the lungs. Since the cloning of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene in 1989, there has been significant interest in the possibility of gene therapy as a treatment for CF. Early studies using viral vectors carrying a healthy CFTR plasmid highlighted the difficulties with overcoming the body's host defences. This article reviews the work on gene therapy in CF to date and describes the ongoing work of the UK CF Gene Therapy Consortium in investigating the potential of gene therapy as a treatment for patients with CF.

  • Cystic Fibrosis
  • Respiratory
  • Genetics
  • Therapeutics
  • Pharmacology

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.